Eledon Pharmaceuticals, Inc. - Common Stock (ELDN) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
ELDN on Nasdaq
Shares outstanding
78,822,261
Price per share
$1.51
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
36,469,559
Total reported value
$94,453,818
% of total 13F portfolios
0%
Share change
-4,359,282
Value change
-$12,219,067
Number of holders
82
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Eledon Pharmaceuticals, Inc. - Common Stock (ELDN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Coastlands Capital LP 6% $20,717,706 4,762,691 Matthew D. Perry 19 Nov 2025
BlackRock, Inc. 4.6% -16% $5,474,994 +$563,100 3,625,824 +11% BlackRock, Inc. 31 Dec 2025
VANGUARD GROUP INC 5.5% $10,286,987 3,318,383 The Vanguard Group 30 Jun 2025
ARMISTICE CAPITAL, LLC 5% $8,879,275 3,137,553 Armistice Capital, LLC 31 Dec 2024
Frazier Life Sciences Public Fund, L.P. 2% $3,330,160 1,176,735 James N. Topper 31 Dec 2024

As of 30 Sep 2025, 82 institutional investors reported holding 36,469,559 shares of Eledon Pharmaceuticals, Inc. - Common Stock (ELDN). This represents 46% of the company’s total 78,822,261 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Eledon Pharmaceuticals, Inc. - Common Stock (ELDN) together control 44% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BVF INC/IL 8% 6,293,282 0% 0.66% $16,299,600
RA CAPITAL MANAGEMENT, L.P. 4.5% 3,566,338 0% 0.11% $9,236,815
BlackRock, Inc. 4.4% 3,465,082 +6.5% 0% $8,974,562
VANGUARD GROUP INC 4.1% 3,267,783 -1.5% 0% $8,463,558
Siren, L.L.C. 2.6% 2,072,767 +200% 0.21% $5,368,467
Zimmer Partners, LP 2.3% 1,825,000 +86% 0.12% $4,726,750
GEODE CAPITAL MANAGEMENT, LLC 1.7% 1,368,940 -1.1% 0% $3,546,137
WELLINGTON MANAGEMENT GROUP LLP 1.6% 1,283,939 0% $3,325,402
SPHERA FUNDS MANAGEMENT LTD. 1.6% 1,280,233 -35% 0.79% $3,315,803
Ensign Peak Advisors, Inc 1.6% 1,264,919 0% 0.01% $3,276,140
Nantahala Capital Management, LLC 1.4% 1,141,237 0% 0.18% $2,955,804
Catalio Capital Management, LP 1.3% 1,061,132 0.51% $2,748,332
Blue Owl Capital Holdings LP 1.2% 979,912 -26% 0.79% $2,537,972
Sanofi 1% 814,980 0% 0.81% $2,110,798
Woodline Partners LP 1% 800,822 -52% 0.01% $2,074,129
Kovitz Investment Group Partners, LLC 0.93% 732,975 0.01% $1,898,405
STATE STREET CORP 0.83% 655,476 +8.3% 0% $1,697,683
22NW, LP 0.81% 636,364 0% 0.86% $1,648,183
CM Management, LLC 0.76% 600,000 +60% 1.3% $1,554,000
NORTHERN TRUST CORP 0.54% 428,562 -5.6% 0% $1,109,976
RENAISSANCE TECHNOLOGIES LLC 0.44% 349,200 +83% 0% $904,428
Velan Capital Investment Management LP 0.44% 346,973 +2.4% 0.84% $898,660
MORGAN STANLEY 0.3% 239,159 -31% 0% $619,423
JANE STREET GROUP, LLC 0.25% 195,201 0% $505,570
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.21% 162,842 -8.1% 0% $421,761

Institutional Holders of Eledon Pharmaceuticals, Inc. - Common Stock (ELDN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 727,559 $1,098,253 +$946,987 $1.51 4
2025 Q3 36,469,559 $94,453,818 -$12,219,067 $2.59 82
2025 Q2 40,843,175 $110,685,079 +$5,557,128 $2.71 85
2025 Q1 38,448,901 $130,340,726 -$2,283,035 $3.39 83
2024 Q4 38,479,556 $158,542,263 +$81,995,664 $4.12 75
2024 Q3 18,485,827 $46,028,922 +$410,879 $2.49 33
2024 Q2 18,259,810 $48,206,187 +$22,892,460 $2.64 31
2024 Q1 9,595,061 $19,765,324 +$914,972 $2.06 28
2023 Q4 9,153,168 $16,475,058 +$507,100 $1.80 28
2023 Q3 8,917,722 $12,217,005 -$169,066 $1.37 28
2023 Q2 9,275,200 $12,707,758 +$2,933,022 $1.37 32
2023 Q1 6,240,661 $14,727,632 -$15,081 $2.36 29
2022 Q4 6,249,493 $14,376,182 -$295,734 $2.28 26
2022 Q3 6,266,937 $17,295,971 -$726,078 $2.76 26
2022 Q2 6,534,650 $15,944,119 -$1,242,137 $2.44 28
2022 Q1 7,004,967 $27,598,192 -$4,350,167 $3.94 31
2021 Q4 7,884,710 $34,745,775 -$3,532,207 $4.41 35
2021 Q3 8,434,580 $52,123,569 -$6,530,250 $6.18 32
2021 Q2 9,423,370 $74,528,000 +$5,446,422 $7.91 30
2021 Q1 8,317,680 $88,956,000 +$88,565,948 $10.70 32
2020 Q4 36,111 $556,000 +$556,001 $15.40 1